Nomura Asset Management International 13F: Cuts BBIO Stake by $14M

Nomura Asset Management International has trimmed its position in BridgeBio Pharma, Inc. (NasdaqGS: BBIO). According to its latest 13F filing with the SEC, Nomura cut its holdings by 190,530 shares, an 11% decrease, leaving it with 1,534,736 shares valued at approximately $114.3 million as of the reporting period.

What Changed in Nomura Asset Management's BridgeBio Pharma Position

Nomura Asset Management reduced its stake in BridgeBio Pharma by 190,530 shares, bringing its total holdings to 1,534,736 shares. This represents an 11% decrease from its previous count of 1,725,266 shares. The value of Nomura's holding in BridgeBio now stands at about $114.3 million.

Other Institutional Activity in BridgeBio Pharma

Several other institutional investors have also adjusted their holdings in BridgeBio Pharma. BlackRock, Inc. reduced its position by 341,772 shares, holding a total of 14,207,757 shares valued at approximately $1.06 billion. Janus Henderson Group PLC increased its stake by 2,178,556 shares, ending with 13,179,013 shares worth around $978.6 million, marking a 19.8% increase. Viking Global Investors LP cut its holdings by 2,551,500 shares, now holding 11,842,434 shares valued at $879.4 million, a 17.7% decrease. Meanwhile, Farallon Capital Management LLC grew its position by 367,000 shares, resulting in 9,365,463 shares worth about $695.5 million.

BridgeBio Pharma, Inc. Stock Up 10.9%

Shares of BridgeBio Pharma (NasdaqGS: BBIO) traded near $74.48 on Wednesday. The company has a market capitalization of approximately $14.59 billion, with a forward P/E ratio of 141.3 and a beta of 0.975. The stock's 52-week range spans from $41.80 to $84.94. Its 50-day moving average is $68.82, while the 200-day moving average stands at $68.05. The company's liquidity ratios include a current ratio of 1.52 and a quick ratio of 1.40.

Recent Earnings

BridgeBio Pharma reported revenue of $579.96 million, reflecting a growth rate of 66.8%. Despite this, the company is not yet profitable, with a negative net margin of -124.4%. The next earnings report is expected on May 7, 2026.

Insider Buying and Selling at BridgeBio Pharma, Inc.

Recent insider activity at BridgeBio Pharma includes several transactions by Jennifer Cook. On June 24, 2026, she purchased 37,167 shares at an average price of $12.28 and sold the same amount under a planned sale at $70.00. Additionally, Hannah Valantine sold 2,196 shares at $68.57 on June 23, 2026, as part of a planned transaction.

Analysts Set New Price Targets

Analysts continue to show confidence in BridgeBio Pharma. On June 16, 2026, Mizuho maintained a 'buy' rating with a $96 price target. Canaccord Genuity initiated coverage with a 'buy' rating and a $104 target on June 3, 2026. Citigroup began coverage with a 'hold' rating and an $82 target on May 19, 2026. The overall analyst consensus is a strong buy, with a mean target price of $102.28.

About BridgeBio Pharma

BridgeBio Pharma, Inc. is a biopharmaceutical company based in Palo Alto, California. It focuses on discovering, developing, and delivering medicines for patients with genetic diseases. The company's portfolio includes treatments for cardiomyopathy, molybdenum cofactor deficiency, achondroplasia, and other rare conditions. Founded in 2015, BridgeBio employs 834 people and is led by CEO Dr. Neil Kumar.

Bottom Line

Nomura Asset Management's recent reduction in its BridgeBio Pharma holdings is a typical portfolio adjustment that investors watch closely. Such filings provide insight into institutional sentiment, although they reflect past positions rather than current ones. With strong analyst support and ongoing developments in its drug pipeline, BridgeBio remains a company of interest in the biotech sector.